MedTrace Logo

Immune Response to Influenza Vaccine in ESRD Patients

NCT04122222 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-10-10

No results posted yet for this study

Summary

On-line hemodiafiltration (HDF) clears more azotaemic toxins compared to high-flux hemodialysis (HD). The response to vaccination is impaired in dialysis patients. We aimed to study the immune responses to influenza vaccine in dialysis patients treated by HDF vs. HD.

Conditions

Interventions

BIOLOGICAL

Influenza vaccine

A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.

Sponsors & Collaborators

  • Bhumirajanagarindra Kidney Institute, Thailand

    collaborator OTHER

  • Ministry of Health, Thailand

    collaborator OTHER_GOV

  • Mahidol University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-25
Primary Completion
2018-07-20
Completion
2018-07-20

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04122222 on ClinicalTrials.gov